Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Century Therapeutics ( (IPSC) ) just unveiled an update.
Century Therapeutics announced a strategic re-prioritization of its pipeline to focus on four transformative programs, particularly CNTY-308 and CNTY-101, aimed at B-cell mediated autoimmune diseases and malignancies. The company reported a strong cash position, extending its runway into the fourth quarter of 2026, and highlighted its decision to discontinue the ELiPSE-1 trial due to unmet transformational thresholds in late-stage R/R NHL, while emphasizing the potential of CNTY-101 in autoimmune diseases.
More about Century Therapeutics
Century Therapeutics is a biotechnology company focused on developing induced pluripotent stem cell (iPSC)-derived cell therapies for autoimmune diseases and cancer.
YTD Price Performance: -43.46%
Average Trading Volume: 477,732
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $50.01M
Learn more about IPSC stock on TipRanks’ Stock Analysis page.
Trending Articles:
- “The No. 1 Destination for the Most Talented Artists”: Netflix Stock (NASDAQ:NFLX) Notches Up as the Duffer Brothers Consider Jumping Ship
- “Breakthrough EVs”: Ford Stock (NYSE:F) Notches Up on New Battery Details
- “An Equity Stake”: Intel Stock (NASDAQ:INTC) Surges as U.S. Government May Buy In With CHIPS Act Money